Many people incorrectly assume that having a disability lowers a person’s quality of life. Christopher Lunsford, MD, assistant professor of orthopaedic surgery, wants to change that misconception. Lunsford works to increase the conversation around disability as a facet of diversity, emphasizing that disability advocacy can and should be a focus of institutional excellence. Building a stronger disability consciousness, he says, can help improve treatment for patients and teaching for students and trainees.

A. Eugene Washington, M.D., chancellor for health affairs at Duke University and president and chief executive officer for the Duke University Health System, has announced that he will step down from the roles on June 30, 2023.

Duke University’s Office for Translation & Commercialization continues to grow and set new records for commercializing innovations, according to just-released fiscal year 2022 data. Duke spawned 14 new companies in the fiscal year including four from the School of Medicine

When it comes to diseases like dementia, Parkinson’s, and ALS, Duke University cell biologist Chantell Evans thinks it’s time to look specifically at neurons. By unraveling how neurons deal with malfunctioning mitochondria, her work could open up possibilities for treating many currently incurable conditions.

Two researchers from Duke University School of Medicine and one from Duke’s Department of Biology have been named recipients of the 2022 Science Diversity Leadership Awards from the Chan Zuckerberg

A study led by the Duke Clinical Research Institute (DCRI) in partnership with Vanderbilt University found no symptomatic or clinical benefit to taking the antidepressant fluvoxamine 50 mg twice daily for 10 days for the treatment of mild-to-moderate COVID-19 symptoms.

It’s all too common for cancer patients to hear their doctors tell them they are no longer responding to their current treatment.

For decades, medical cancer treatment has generally meant chemotherapy, radiation, or surgery, alone or in combination. Today, new approaches such as immunotherapies and targeted therapies are becoming available, with many more in research and development.

Nicole Calakos, MD, PhD, a professor of neurology and Lincoln Financial Group Distinguished Professor of Neurobiology, has been elected to the U.S. National Academy of Medicine (NAM).  

L. Ebony Boulware, MD, MPH, Director of the Duke Clinical and Translational Science Institute (CTSI), will step down from her positions at Duke on December 31, 2022, to begin a new role as Dean of the Wake Forest University School of Medicine in January 2023.